Low prevalence of (pre) malignant lesions in the breast and high prevalence in the ovary and fallopian tube in women at hereditary high risk of breast and ovarian cancer

International Journal of Cancer

Volumn 119, Issue 6, 2006, Pages 1412-1418

  Hermsen, Brenda B J ^a   Van Diest, Paul J ^b   Berkhof, Johannes ^a   Menko, Fred H ^a   Gille, Johan J P ^a   Piek, Jurgen M J ^a   Meijer, Sybren ^a   Winters, Henri A H ^a   Kenemans, Peter ^a   Von Mensdorff Pouilly, Silvia ^a   Verheijen, René H M ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

BRCA1 2; Breast; Ovary; Premalignant lesions

Indexed keywords

ADULT; AGE; ARTICLE; BRCA2 GENE; BREAST CANCER; BREAST REDUCTION; CONTROLLED STUDY; FEMALE; GENE MUTATION; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MASTECTOMY; ONCOGENE; OVARY CANCER; PRECANCER; PREVALENCE; PRIORITY JOURNAL; SALPINGOOOPHORECTOMY; UTERINE TUBE CARCINOMA;

ADULT; AGED; BREAST NEOPLASMS; FALLOPIAN TUBE NEOPLASMS; FEMALE; GENES, BRCA1; GENES, BRCA2; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MASTECTOMY; MIDDLE AGED; OVARIAN NEOPLASMS; OVARIECTOMY; PREVALENCE; RISK FACTORS;

EID: 33747478190     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.21988     Document Type: Article

References (57)

1. Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, Liu Q, Cochran C, Bennett LM, Ding W. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994;266:66-71.
2. Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion J, Collins N, Gregory S, Gumbs C, Micklem G. Identification of the breast cancer susceptibility gene BRCA2. Nature 1995;378:789-92.
3. Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE. Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Lancet 1994;343:692-5.
4. Struewing JP, Hartge P, Wacholder S, Baker SM, Berlin M, McAdams M, Timmerman MM, Brody LC, Tucker MA. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 1997;336:1401-8.
5. Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, Loman N, Olsson H, Johannsson O, Borg A, Pasini B, Radice P et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history, a combined analysis of 22 studies. Am J Hum Genet 2003;72:1117-30.
6. Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P, Bishop DT, Weber B, Lenoir G, Chang-Claude J, Sobol H, Teare MD et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 1998;62:676-89.
7. Levine DA, Argenta PA, Yee CJ, Marshall DS, Olvera N, Bogomolniy F, Rahaman JA, Robson ME, Offit K, Barakat RR, Soslow RA, Boyd J. Fallopian tube and primary peritoneal carcinomas associated with BRCA mutations. J Clin Oncol 2003;21:4222-7.
8. Aziz S, Kuperstein G, Rosen B, Cole D, Nedelcu R, McLaughlin J, Narod SA. A genetic epidemiological study of carcinoma of the Fallopian tube. Gynecol Oncol 2001;80:341-5.
9. Zweemer RP, van Diest PJ, Verheijen RH, Ryan A, Gille JJ, Sijmons RH, Jacobs IJ, Menko FH, Kenemans P. Molecular evidence linking primary cancer of the Fallopian tube to BRCA1 germline mutations. Gynecol Oncol 2000;76:45-50.
10. Brose MS, Rebbeck TR, Calzone KA, Stopfer JE, Nathanson KL, Weber BL. Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J Natl Cancer Inst 2002;94:1365-72.
11. Hartmann LC, Schaid DJ, Woods JE, Crotty TP, Myers JL, Arnold PG, Petty PM, Sellers TA, Johnson JL, McDonnell SK, Frost MH, Jenkins RB. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med 1999;340:77-84.
12. Rebbeck TR, Friebel T, Lynch HT, Neuhausen SL, Van't Veer L, Garber JE, Evans GR, Narod SA, Isaacs C, Matloff E, Daly MB, Olopade OI et al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol 2004;22:1-8.
13. Metcalfe K, Lynch HT, Ghadirian P, Tung N, Olivotto I, Warner E, Olopade IO, Eisen A, Weber B, McLennan J, Sun P, Foulkes WD et al. Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol 2004;22:2328-35.
14. Kauff ND, Satagopan JM, Robson ME, Scheuer L, Hensley M, Hudis CA, Ellis NA, Boyd J, Borgen PI, Barakat RR, Norton L, Castiel M et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2002;346:1609-15.
15. Rebbeck TR, Lynch HT, Neuhausen SL, Narod SA, Van't Veer L, Garber JE, Evans G, Isaacs C, Daly MB, Matloff E, Olopade OI, Weber BL. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 2002;346:1616-22.
16. Rebbeck TR, Levin AM, Eisen A, Snyder C, Watson P, Cannon-Albright L, Isaacs C, Olopade O, Garber JE, Godwin AK, Daly MB, Narod SA et al. Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. J Natl Cancer Inst 1999;91:1475-9.
17. Hoogerbrugge N, Bull P, Widt-Levert LM, Beex LV, Kiemeney LA, Ligtenberg MJ, Massuger LF, Boetes C, Manders P, Brunner HG. High prevalence of premalignant lesions in prophylactically removed breasts from women at hereditary risk for breast cancer. J Clin Oncol 2003;21:41-5.
18. Khurana KK, Loosmann A, Numann PJ, Khan SA. Prophylactic mastectomy: athologic findings in high-risk patients. Arch Pathol Lab Med 2000;124:378-81.
19. Kauff ND, Brogi E, Scheuer L, Pathak DR, Borgen PI, Hudis CA, Offit K, Robson ME. Epithelial lesions in prophylactic mastectomy specimens from women with BRCA mutations. Cancer 2003;97:1601-8.
20. Adem C, Reynolds C, Soderberg CL, Slezak JM, McDonnell SK, Sebo TJ, Schaid DJ, Myers JL, Sellers TA, Hartmann LC, Jenkins RB. Pathologic characteristics of breast parenchyma in patients with hereditary breast carcinoma, including BRCA1 and BRCA2 mutation carriers. Cancer 2003;97:1-11.
21. Lu KH, Garber JE, Cramer DW, Welch WR, Niloff J, Schrag D, Berkowitz RS, Muto MG. Occult ovarian tumors in women with BRCA1 or BRCA2 mutations undergoing prophylactic oophorectomy. J Clin Oncol 2000;18:2728-32.
22. Leeper K, Garcia R, Swisher E, Goff B, Greer B, Paley P. Pathologic findings in prophylactic oophorectomy specimens in high-risk women. Gynecol Oncol 2002;87:52-6.
23. Paley PJ, Swisher EM, Garcia RL, Agoff SN, Greer BE, Peters KL, Goff BA. Occult cancer of the Fallopian tube in BRCA1 germline mutation carriers at prophylactic oophorectomy: a case for recommending hysterectomy at surgical prophylaxis. Gynecol Oncol 2001;80:176-80.
24. Colgan TJ, Murphy J, Cole DE, Narod S, Rosen B. Occult carcinoma in prophylactic oophorectomy specimens: prevalence and association with BRCA germline mutation status. Am J Surg Pathol 2001;25:1283-9.
25. Carcangiu ML, Radice P, Manoukian S, Spatti G, Gobbo M, Pensotti V, Crucianelli R, Pasini B. Atypical epithelial proliferation in Fallopian tubes in prophylactic salpingo-oophorectomy specimens from BRCA1 and BRCA2 germline mutation carriers. Int J Gynecol Pathol 2004;23:35-40.
26. Piek JM, van Diest PJ, Zweemer RP, Jansen JW, Poort-Keesom RJ, Menko FH, Gille JJ, Jongsma AP, Pals G, Kenemans P, Verheijen RH. Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer. J Pathol 2001;195:451-6.
27. Kriege M, Brekelmans CT, Boetes C, Besnard PE, Zonderland HM, Obdeijn IM, Manoliu RA, Kok T, Peterse H, Tilanus-Linthorst MM, Muller SH, Meijer S et al. Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N Engl J Med 2004;351:427-37.
28. Sevilla C, Moatti JP, Julian-Reynier C, Eisinger F, Stoppa-Lyonnet D, Bressac-de Paillerets B, Sobol H. Testing for BRCA1 mutations: a cost-effectiveness analysis. Eur J Hum Genet 2002;10:599-606.
29. Hogervorst FBL, Nederlof PM, Gille JJP, McElgunn CJ, Grippeling M, Pruntel R, Regnerus R, van Weisem T, van Spaendonk R, Menko FH, Kluijt I, Dommering C et al. Large genomic deletions and duplications in the BRCA1 gene identified by a novel quantitative method. Cancer Res 2003;63:1449-53.
30. Page DL, Dupont WD, Rogers LW, Rados MS. Atypical hyperplastic lesions of the female breast. A long-term follow-up study. Cancer 1985;55:2698-708.
31. Holland R, Peterse JL, Millis RR, Eusebi V, Faverly D, van de Vijver MJ, Zafrani B. Ductal carcinoma in situ: a proposal for a new classification. Semin Diagn Pathol 1994;11:167-80.
32. Fox H. Pathology of early malignant change in the ovary. Int J Gynecol Pathol 1993;12:153-5.
33. Schlosshauer PW, Cohen CJ, Penault-Llorca F, Miranda CR, Bignon YJ, Dauplat J, Deligdisch L. Prophylactic oophorectomy: a morphologic and immunohistochemical study. Cancer 2003;98:2599-606.
34. Finch A, Shaw P, Rosen B, Murphy J, Narod SA, Colgan TJ. Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers. Gynecol Oncol 2006;100:58-64.
35. Piek JM, Verheijen RH, Kenemans P, Massuger LF, Bulten H, van Diest PJ. BRCA1/2-related ovarian cancers are of tubal origin: a hypothesis. Gynecol Oncol 2003;90:491.
36. Pere H, Tapper J, Seppala M, Knuutila S, Butzow R. Genomic alterations in Fallopian tube carcinoma: comparison to serous uterine and ovarian carcinomas reveals similarity suggesting likeness in molecular pathogenesis. Cancer Res 1998;58:4274-6.
37. Olivier RI, van Beurden M, Lubsen MA, Rookus MA, Mooij TM, van de Vijver MJ, Van't Veer LJ. Clinical outcome of prophylactic oophorectomy in BRCA1/BRCA2 mutation carriers and events during follow-up. Br J Cancer 2004;90:1492-7.
38. Piek JM, Verheijen RH, Menko FH, Jongsma AP, Weegenaar J, Gille JJ, Pals G, Kenemans P, van Diest PJ. Expression of differentiation and proliferation related proteins in epithelium of prophylactically removed ovaries from women with a hereditary female adnexal cancer predisposition. Histopathology 2003;43:26-32.
39. Kerner R, Sabo E, Gershoni-Baruch R, Beck D, Ben-Izhak O. Expression of cell cycle regulatory proteins in ovaries prophylactically removed from Jewish Ashkenazi BRCA1 and BRCA2 mutation carriers: correlation with histopathology. Gynecol Oncol 2005;99:365-75.
40. Lakhani SR. The transition from hyperplasia to invasive carcinoma of the breast. J Pathol 1999;187:272-8.
41. Beckmann MW, Niederacher D, Schnurch HG, Gusterson BA, Bender HG. Multistep carcinogenesis of breast cancer and tumour heterogeneity. J Mol Med 1997;75:429-39.
42. van Diest PJ. Ductal carcinoma in situ in breast carcinogenesis. J Pathol 1999;187:383,384.
43. Marshall LM, Hunter DJ, Connolly JL, Schnitt SJ, Byrne C, London SJ, Colditz GA. Risk of breast cancer associated with atypical hyperplasia of lobular and ductal types. Cancer Epidemiol Biomarkers Prev 1997;6:297-301.
44. Page DL, Schuyler PA, Dupont WD, Jensen RA, Plummer WD, Jr, Simpson JF. Atypical lobular hyperplasia as a unilateral predictor of breast cancer risk: a retrospective cohort study. Lancet 2003;361:125-9.
45. Hartmann LC, Sellers TA, Frost MH, Lingle WL, Degnim AC, Ghosh K, Vierkant RA, Maloney SD, Pankratz VS, Hillman DW, Suman VJ, Johnson J et al. Benign breast disease and the risk of breast cancer. N Engl J Med 2005;353:229-37.
46. King MC, Marks JH, Mandell JB. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 2003;302:643-6.
47. Adem C, Jenkins RB, Capron F, Stoppa-Lyonnet D. High-risk lesions in high-risk women: a high-risk formalin-based biology. J Clin Oncol 2004;22:1159-61.
48. Suris-Swartz PJ, Schildkraut JM, Vine MF, Hertz-Picciotto I. Age at diagnosis and multiple primary cancers of the breast and ovary. Breast Cancer Res Treat 1996;41:21-9.
49. Fishman A, Dekel E, Chetrit A, Lerner-Geva L, Bar-Am A, Beck D, Beller U, Ben-Baruch G, Piura B, Friedman E, Struewing JP, Modan B. Patients with double primary tumors in the breast and ovary-clinical characteristics and BRCA1-2 mutations status. Gynecol Oncol 2000;79:74-8.
50. Einbeigi Z, Meis-Kindblom JM, Kindblom LG, Wallgren A, Karlsson P. Clustering of individuals with both breast and ovarian cancer-a possible indicator of BRCA founder mutations. Acta Oncol 2002;41:153-7.
51. Cvelbar M, Ursic-Vrscaj M, Rakar S. Risk factors and prognostic factors in patients with double primary cancer: epithelial ovarian cancer and breast cancer. Eur J Gynaecol Oncol 2005;26:59-63.
52. Payne DK, Biggs C, Tran KN, Borgen PI, Massie MJ. Women's regrets after bilateral prophylactic mastectomy. Ann Surg Oncol 2000;7:150-4.
53. Meiser B, Tiller K, Gleeson MA, Andrews L, Robertson G, Tucker KM. Psychological impact of prophylactic oophorectomy in women at increased risk for ovarian cancer. Psychooncology 2000;9:496-503.
54. Hopwood P, Lee A, Shenton A, Baildam A, Brain A, Lalloo F, Evans G, Howell A. Clinical follow-up after bilateral risk reducing ('prophylactic') mastectomy: mental health and body image outcomes. Psychooncology 2000;9:462-72.
55. Metcalfe KA, Esplen MJ, Goel V, Narod SA. Psychosocial functioning in women who have undergone bilateral prophylactic mastectomy. Psychooncology 2004;13:14-25.
56. Tiller K, Meiser B, Butow P, Clifton M, Thewes B, Friedlander M, Tucker K. Psychological impact of prophylactic oophorectomy in women at increased risk of developing ovarian cancer: a prospective study. Gynecol Oncol 2002;86:212-19.
57. Fry A, Busby-Earle C, Rush R, Cull A. Prophylactic oophorectomy versus screening: psychosocial outcomes in women at increased risk of ovarian cancer. Psychooncology 2001;10:231-41.